Posted inHealthcare Highlight News
Takeda Pharmaceuticals Initiates Plasma-Derived Therapy for COVID-19
An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed by the company to treat infected, high-risk individuals. Takeda Pharmaceutical Company Ltd. has said it will share with members of the United States Congress the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with coronavirus outbreak, while…